GlassScriptPhysician profile
Jamshid Niknam
NPI 1134132798
$7,387.27
in general payments reported to CMS, 2019-2025
41 companies · $908 in 2025
The $908 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $1,187 · 2021: $1,267 · 2022: $1,276 · 2023: $762 · 2024: $787 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.40 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $860.11 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $790.17 | 2019-2025 | Fasenra, Breztri, Symbicort |
| Actelion Pharmaceuticals US, INC. | $683.84 | 2020-2025 | Uptravi, Opsumit, Opsynvi |
| Sunovion Pharmaceuticals INC. | $617.45 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.58 | 2019-2025 | Ofev |
| Mallinckrodt Hospital Products INC. | $348.36 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $304.21 | 2019-2024 | |
| Genzyme Corporation | $268.30 | 2022-2025 | |
| Philips North America LLC | $259.32 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $213.03 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $195.58 | 2021-2022 | |
| Lilly USA, LLC | $195.52 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Gilead Sciences, INC. | $193.51 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $172.00 | 2019 | |
| Insmed, INC. | $171.84 | 2023-2025 | Arikayce |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamshid Niknam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.